Fig 1.
Number of variants and genes present after initial filtering and biological filtering.
Table 1.
Characteristics of women with (cases) and without (controls) preeclampsia.
Table 2.
Whole-exome sequencing quality data.
Fig 2.
Comparison of the 100 most variable biological processes in cases and controls.
Variant processes were identified with the disease association panel (A-D) or the gene panel (E-G). A: The number of unique and shared variant harbouring processes. For shared variant processes, correlation of total variant number (B) and number of genes carrying variants (C). Number of variants in 40 processes which less frequently carried variants in cases (D). E: Number of unique and shared variant processes. For shared variant harbouring processes, correlation of total variant number (F) and number of genes carrying variants (G).
Fig 3.
Comparison of the 100 most variable pathways in cases and controls.
Variant pathways were identified with the disease association panel (A-C) or the gene panel (C-F). A: Number of unique and shared variant harbouring pathways. For shared variant pathways, correlations of total variant number and number of genes carrying variants are presented in B and C, respectively. D: Number of unique and shared variant harbouring pathways. For shared variant pathways, correlations of total variant number and number of genes carrying variants are presented in E and F.
Fig 4.
Comparison of variant genes in cases and controls.
Genes containing variants were identified with the disease association panel (A-C) or the gene panel (C-F). A: Number of unique and shared variant harbouring genes. For the shared genes, correlation of total variant number is depicted in B. C: Genes with extreme distribution of variant numbers between groups (uncorrected p-values below 0.05). D: Number of unique and shared variant harbouring pathways. For the shared genes, correlation of total variant number is depicted in E. F: Genes with extreme distribution of variant numbers between groups (uncorrected p-values below 0.05).
Table 3.
Rare predicted deleterious variants found in ≥10% of women with preeclampsia (cases) and 2% of controls.
Table 4.
Predicted deleterious variants in ROCK2, AVCR2A, ERAP1, and ERAP2 in women with (cases) and without (controls) preeclampsia.